Navigation Links
China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
Date:9/2/2008

HARBIN, China, Sept. 2 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (AMEX: CSY), a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has received approval to list its common stock on the NASDAQ Global Market.

China Sky One expects to start trading on the NASDAQ Global Market on September 15, 2008, and that the last day of trading on the American Stock Exchange ("AMEX") will be September 12, 2008. The trading symbol for China Sky One's common stock on the NASDAQ Global Market will be "CSKI". The Company primarily sells its products in the People's Republic of China (PRC).

"We are very excited to list on NASDAQ and consider the change to be a significant milestone in China Sky One's development as a U.S. public company," commented Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One. "We are confident that the listing on NASDAQ will allow us to further enlarge our investor base and increase both our liquidity and visibility in the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit

SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
2. ORBIS and Alcon Train Chinas Next Generation of Sight-Savers
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
5. China Kangtai Cactus Biotech Announces Record Second Quarter Results
6. China Biologic Products Reports Second Quarter 2008 Results
7. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
8. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
9. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
10. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
11. China Medicine Announces Strong Second Quarter 2008 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...LPHIA, Dec. 3 Shire plc ...biopharmaceutical company, today announced a volun...drawal of one lot of the Attention-Deficit/Hyperac...re is taking this action because some Daytrana pat...ir release liner removal specification, and as a r...
(Date:12/3/2009)...TON, Mass., Dec. 3 Calip... provider of tools and services for drug discovery...ng Image 4.0 software for IVIS® in vivo imagi...than 800 Caliper IVIS systems currently installed ...es advanced spectral unmixing tools to enhance flu...
(Date:12/2/2009)...hilippines, Dec. 2 Spectrum Blue S...en energy companies on the planet. Through the eff...net,s President and Recycling Specialist Leroy Joh...over 25 years, stated that Spectrum Blue Steel is ...tage for spectacular earnings because of the bi pr...
(Date:12/2/2009)...W YORK, Dec. 2 Reportlinker.com an...able in its catalogue: ,, Drug Discovery Techn...pportunities ,, http://www.reportlinker.com/p...ate-of-Market-Trends--Opportunities.html ,, Dr...ement of every pharmaceutical company,s business s...
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
...ia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ), a l...n researching,developing, manufacturing and market...at, in accordance with the relevant provisions iss...ing Provincial Department of Finance,National Reve...nue Department,in Liaoning Province, the Company h...
...es, Inc. (NYSE Alternext US: PTN) reported that it...nuary 23, 2009 has been accepted by the NYSE Alter... American Stock Exchange). , , As reported on De...Exchange that it was not in compliance with certai...03(a)(ii) and (iii) of the Exchange,s Company Guid...
...- Proceeds to Facilitate Clinical Development of L...in the development of innovative conjugated,vaccin...F25 million (ca.,US$22 million, EUR17 million) Ser...thschild Investment Partners. Existing investors, ...heir commitment to the future of the company,throu...
Other Biology Technology:Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext US 2GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners 2
(Date:12/2/2009)...e status did not prompt people participating in a ... screening program to pick up their cigarettes aga...cer Epidemiology, Biomarkers & Prevention , a jour...h. The December issue contains a special focus on ...ad concern in the lung screening community that re...
(Date:12/2/2009)...uate students from Stevens Institute of Technology...st hosted by the International Society for Pharmac... highlights the research conducted by the students...g in San Diego, Calif. , The winning poster, tit...ensioning Device," was presented by Aaron Rella, a...
(Date:12/2/2009)...s pleased to announce the 2009 winner of the Inter...ker Distinguished Service Professor Emeritus, Depa... Biology, The University of Chicago, USA. , The...15th anniversary of the Manpei Suzuki Diabetes Fou...rchers in the field of diabetes around the world w...
Breaking Biology News(10 mins):Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Structural biology scores with protein snapshot 9011 1Structural biology scores with protein snapshot 9011 2Structural biology scores with protein snapshot 9011 3Alzheimers Disease 3A Facing the Facts Public Television Documentary Wins Emmy Award 50107 1Alzheimers Disease 3A Facing the Facts Public Television Documentary Wins Emmy Award 50107 2Alzheimers Disease 3A Facing the Facts Public Television Documentary Wins Emmy Award 50107 3Alzheimers Disease 3A Facing the Facts Public Television Documentary Wins Emmy Award 50107 4Popular Jellyfish Sting Treatment Also Proven Effective on Stings From Portuguese Man of War 50105 1Popular Jellyfish Sting Treatment Also Proven Effective on Stings From Portuguese Man of War 50105 2Popular Jellyfish Sting Treatment Also Proven Effective on Stings From Portuguese Man of War 50105 3
...al trial of a recombinant vaccine for the deadly t...results indicate the vaccine is safe and effective...T Southwestern Medical Center researchers report. ...groups of five volunteers each. Individuals in eac...arious doses of the vaccine, called RiVax, over th...
...er have uncovered part of the genetic mechanism th...ked arteries. , A team led by SFVAMC vascular surg... mice that the MMP2 gene is essential for the grow...s blocked. , The team also identified and descri...s of the MMP2 gene that are expressed when new art...
...rookhaven National Laboratory have just launched a...of the brain of a popular laboratory mouse (see h...s around the world can now download these extremel...p other data -- such as which parts of the brain a... are expressed -- and for making quantitative anat...
Other Biology News:Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 2Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 3Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 4Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3
Rabbit Anti-EEF2K Monoclonal Antibody, Unconjugated, Clone EP881Y from Abcam
Human Regulatory T cell (Foxp3 / CD4 / CD25) Flow Cytometry staining Kit from eBioscience
Weinreb Linker from ChemPep, Inc.
Goat Anti-VAV2 Antibody, Unconjugated from Raybiotech, Inc.
Biology Products: